GlassScriptPhysician profile
Venugopal Thirumurti
NPI 1073688040
$1,306.99
in general payments reported to CMS, 2019-2025
19 companies · $89.01 in 2025
The $89.01 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $104 · 2021: $300 · 2022: $144 · 2023: $73.08 · 2024: $357 · 2025: $89.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $284.54 | 2019-2024 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Janssen Pharmaceuticals, INC | $178.91 | 2020-2024 | Xarelto |
| Abiomed | $148.51 | 2024 | Impella |
| Amarin Pharma, INC. | $124.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.69 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.81 | 2020-2025 | Jardiance |
| Lantheus Medical Imaging, INC. | $59.62 | 2019-2022 | |
| Medtronic Vascular, INC. | $53.34 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $48.94 | 2024 | Arcalyst |
| Pfizer INC. | $32.94 | 2022-2023 | |
| Boston Scientific Corporation | $29.78 | 2021 | |
| Abbott Laboratories | $29.15 | 2025 | Mitraclip |
| Novo Nordisk INC | $26.59 | 2023-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $25.02 | 2020 | |
| Amgen INC. | $20.11 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.10 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.62 | 2019-2020 | |
| Scpharmaceuticals INC. | $17.78 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.17 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venugopal Thirumurti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.